Dean Tuck – Managing Director – Dreadnought Resources (ASX:DRE) is a highly active West Australian mineral explorer focused on finding the metals needed now and in the future.
Copyright 2024 – Finance News Network
16 Apr 2021 - Novatti Group Limited (ASX:NOV) CEO Peter Cook talks about the growing demand for digital payments and the opportunities this presents for the company.
25 Oct 2023 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow discusses efficacy results for the company's glioblastoma therapy.
01 Apr 2022 - Lepidico Limited (ASX:LPD) Managing Director Joe Walsh discusses the progress of the company's Karibib lithium operations and Abu Dhabi processing plant, potential capital raisings and offtake agreements.
11 Jun 2020 - MGM Wireless Limited (ASX:MWR) CEO, Mark Fortunatow talks about growth in the company's SPACETALK brand of wearables for kids, new product categories, distribution, and growth in wearables from niche product to mainstream.
28 Feb 2024 - Graeme Sloan - Managing Director - Kali Metals (ASX:KM1) is a portfolio of assets that represents one of the largest and most prospective exploration packages across Australia’s world leading hard-rock lithium fields.
19 Dec 2023 - James Powell, General Manager - Investor Relations, Corporate Affairs and Sustainability for Rural Funds Management presents on the FY23 results of the Rural Funds Group (ASX:RFF).
08 Jul 2021 - ImpediMed Limited (ASX:IPD) CEO and Managing Director Richard Carreon discusses the company's bioimpedance spectroscopy platform SOZO, which is particularly targeted at noninvasive clinical assessment and monitoring of fluid status and tissue composition in the treatment of secondary lymphoedema, heart failure and renal failure.
20 Mar 2023 - Magontec Limited (ASX:MGL) Executive Chairman and CEO Nicholas Andrews discusses the magnesium industry, drivers of demand, China, supply chains into the US and Europe, and recent financial results.
11 Dec 2020 - Cyclopharm Limited (ASX:CYC) CEO & Managing Director James McBrayer talks about USFDA approval for Technegas, the company's USA commercialisation plan, and opportunities beyond its key diagnostic market for pulmonary embolism.